Project AI-Write

Confidential Teaser

February 2025



frpadvisory.com

Business Overview

Opportunity to acquire a highly specialised AI-enhanced medical-writing business

Business Opportunity

- > Opportunity to acquire the shares or business and assets of Project AI-Write.
- The business has developed an AI-powered platform designed specifically for medical writers to reduce operational tasks and manual perusal of data. While the Global Medical Writing is a niche market, it is highly lucrative and continues to grow.
- > Within six months, the business had already onboarded its first clients securing £1.26m in funding. Existing funders do not wish to proceed further with the next stage of investment due to a change in ownership with cashflow therefore forecast to become challenging.
- In addition to the IP held by the business, there are also a number of assets used to create and implement the software.
- > The business is ISO, SOC & HIPAA certified.

Process

- > If you would like further information on this opportunity, please contact FRP using the details provided overleaf. All communication on this opportunity should be conducted through FRP, their staff and their agents.
- FRP is requesting indicative proposals, supported by proof of funding, by no later than 4pm (GMT) on **10 March 2025**, with a view to completing shortly thereafter.
- > Further information can be obtained following completion of a non-disclosure agreement via FRP's DataRoom.
- > FRP reserve the right to close the bidding early or extend the deadline, without liability or advanced notice.

Financial Forecast				
	2024	2025	2026	2027
Revenue (£)	264,000	2,431,000	8,327,900	17,274,650
% YoY Growth	-	821%	243%	107%
Direct Costs (£)	(33,445)	(239,481)	(800,692)	(1,823,055)
Gross Profit (£)	230,555	2,191,519	7,527,208	15,451,595
Overhead & Expenses (£)	(1,506,570)	(2,215,509)	(5,002,871)	(7,494,002)
EBITDA (£)	(1,276,016)	(23,990)	2,524,338	7,957,593
% EBITDA	-483%	-1%	30%	46%
Revenue per FTE (£)	24,000	75,969	126,180	174,491
Cust. Acquisition Cost (CAC,£)	59,889	19,319	22,293	29,597
Cust. Lifetime Value ¹ (CLTV,£)	1,152,773	849,426	790,507	850,400
CLTV/CAC indicator	19.2x	44.0x	35.5x	28.7x
Avg. Time-to-Acquire New Customer ²	212.5 Days	45.2 Days	35.1 Days	33.8 Days

Financial forecast & earnings before interest, taxes, depreciation & amortisation ("EBITDA") provided by the business

Important Notice

Purpose

This document (the 'Document') is issued by FRP Advisory Trading Limited ('FRP') on the terms and conditions set out below for the exclusive use of the persons to whom it is addressed and their advisers in connection with the proposed acquisition of the trade and assets of the company that are described in this document, hereafter referred to as the "Company" or "Project AI-Write".

This Document has been compiled by FRP, acting as agents. In issuing this document, FRP is acting for the Company and for no one else in connection with this transaction.

You must carry out your own independent investigation and rely on your own assessment of the business. We recommend that you seek independent professional advice.

Verification of information

EDD

The information contained herein has been prepared to assist the recipient of this Document or their advisers in making their own evaluation of the Company and does not purport to contain all the information that a purchaser may require. This document does not constitute an offer or invitation for the sale, purchase, exchange or transfer of any shares or other securities or any recommendation to enter into a transaction and is not intended to form the basis of any contract or investment decision.

Potential purchasers or investors should conduct their own investigation and analysis of the Company and should satisfy themselves as to the condition of the business of the Company and the accuracy and completeness of the statements contained herein. FRP has not independently verified any information. Neither FRP nor the directors or partners of the Company make any representation or warranty (express or implied) as to the accuracy or completeness of this Document or any other written or oral communication transmitted to potential purchasers or investors in the course of their evaluation of the Company.

The information contained in this Document and any further information relating to the Company supplied by FRP is and will be supplied on the basis that neither FRP nor any partner, employee or agent of FRP nor any director of the companies within the Company is liable for any errors or omissions in this Document or such further information or any loss howsoever arising sustained by any person relying on such information.

Where this Document includes certain statements with respect to the anticipated future performance of the Company and as to the markets for its services and products, such statements reflect various assumptions that may or may not prove to be correct. No representation or warranty (express or implied) is made by FRP or the directors of the companies within the Company as to the accuracy of such statements.

Distribution

This Document is intended for the exclusive use of the potential purchaser or investor and their advisers to which it is being presented and is provided on the express understanding that the information contained herein will be regarded and treated as strictly confidential.

This Document is sent to you relying upon your acknowledgement and acceptance that it is exempt from the general restriction in Section 21 of the Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity, by virtue of the fact that it relates to a transaction or potential transaction that falls within Article 62 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. This Document may not be reproduced or used, in whole or in part for any other purpose, nor furnished to any persons other than those to whom copies have been sent by FRP. By accepting this Document you agree to be bound by the foregoing limitations.

In the United States of America, FRP relies on the no action relief issued by the Division of Trading and Markets of the Securities and Exchange Commission on January 31, 2014 (as revised on February 4, 2014, the "No Action Letter") that permits an M&A Broker to engage in certain activities in connection with the purchase or sale of privately-held companies without registering as a broker-dealer under Section 15(b) of the Exchange Act of 1984.

Contact Information

FRP is seeking indicative proposals by 4pm (GMT) on 10 March 2025 with a view to concluding a transaction within the shortest duration thereafter.

If you would like further information on this opportunity, please contact the following individuals from FRP.

Lianne Maidman

Senior Insolvency Administrator

Tel: +44 (0)1642 917 559

Lianne.maidman@frpadvisorv.com

Bhuvnesh Majupuria Director <u>Bhuvnesh.Majupuria@frpadvisory.com</u> Tel: +44 (0)1642 917 558

Michelle Chatterton Senior Manager <u>Michelle.Chatterton@frpadvisory.com</u> Tel: +44 (0)1138 313 558